Accession Number:

AD1158153

Title:

MYCN Reprograms Neuroblastoma Metabolism

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

BAYLOR COLL OF MEDICINE HOUSTON TX

Report Date:

2021-10-01

Pagination or Media Count:

12

Abstract:

Despite current aggressive regimens, the majority of patients with MYCN amplification die due to drug-resistant disease, and further intensification of chemotherapy will not significantly improve this outcome. We propose an entirely novel strategy to oppose MYCN oncogenic function in NB by blocking the metabolic reprogramming driven by MYCN. Our guiding hypothesis is that lipid metabolism is required for NB tumorigenesis. We have shown that lipid metabolism is a selective metabolic dependency of MYCN-induced tumors. Targeting MYCN-driven lipogenesis effectively blocks in vivo tumor growth in multiple models of NB and sensitize NB tumors to conventional chemotherapy.

Descriptors:

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]